{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:01:34Z","timestamp":1785423694260,"version":"3.56.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of a dropless regimen using intravitreal decanted triamcinolone acetonide and moxifloxacin at the conclusion of pars plana vitrectomy (PPV), compared with standard postoperative topical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study included consecutive patients undergoing PPV at a tertiary retina center. The dropless cohort (May-October 2025) received intravitreal decanted triamcinolone (5 mg) and moxifloxacin (500 \u03bcg). The control cohort, operated during the preceding 6 months, received topical moxifloxacin 0.5% and prednisolone acetate 1%. Outcomes included intraocular inflammation, intraocular pressure (IOP), central subfield thickness (CST), cystoid macular edema (CME), and best-corrected visual acuity (BCVA). A prespecified subgroup analysis was performed for epiretinal membrane (ERM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      172 eyes were included (87 dropless, 85 topical). The dropless group demonstrated significantly less anterior chamber inflammation at week 2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0008) and at month 3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0223). Mean CST was lower at week 2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), month 3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0009), and month 6 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.012). CME incidence was reduced (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). BCVA improvement was greater in the dropless group at week 2 (+15 vs \u20132.5 ETDRS letters;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0003), month 3 (+25 vs +9.5 letters;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), and month 6 (+20 vs +8 letters;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). IOP was similar between groups, and no endophthalmitis occurred. Findings were consistent in the ERM subgroup.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A dropless intravitreal regimen at the conclusion of PPV can be a safe and effective alternative to topical therapy, with reduced postoperative inflammation and CME and improved visual outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004947","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:01:37Z","timestamp":1785420097000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dropless Pars Plana Vitrectomy Using Intravitreal Decanted Triamcinolone and Moxifloxacin: Safety and Efficacy"],"prefix":"10.1097","author":[{"given":"Amr Lotfy","family":"Ali","sequence":"first","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vail","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Sherif","family":"Morsy","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Ophthalmology Department, Faculty of Medicine, Tanta University, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal Nailesh","family":"Mehta","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Jena","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Uwe","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-2500","authenticated-orcid":false,"given":"William R.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"},{"name":"Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:01:37Z","timestamp":1785420097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004947","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}